Cisplatin/gemcitabine or oxaliplatin/gemcitabine in the treatment of advanced biliary tract cancer: a systematic review

吉西他滨 奥沙利铂 养生 顺铂 医学 内科学 肿瘤科 化疗 胃肠病学 癌症 结直肠癌
作者
Frédéric Fiteni,Thierry Nguyen,Déwi Vernerey,Marie‐Justine Paillard,Stefano Chong Hun Kim,Martin Demarchi,F. Fein,Christophe Borg,Franck Bonnetain,Xavier B. Pivot
出处
期刊:Cancer Medicine [Wiley]
卷期号:3 (6): 1502-1511 被引量:84
标识
DOI:10.1002/cam4.299
摘要

Cisplatin/gemcitabine association has been a standard of care for first-line regimen in advanced biliary tract cancer nevertheless oxaliplatin/gemcitabine regimen is frequently preferred. Because comparative effectiveness in clinical outcomes of cisplatin- versus oxaliplatin-containing chemotherapy is not available, a systematic review of studies assessing cisplatin/gemcitabine or oxaliplatin/gemcitabine chemotherapies in advanced biliary tract cancer was performed. Published studies evaluating cisplatin/gemcitabine or oxaliplatin/gemcitabine in advanced biliary tract cancer were included. Each study was weighted according to the number of patients included. The primary objective was to assess weighted median of medians overall survival (mOS) reported for both regimens. Secondary goals were to assess weighted median of medians progression-free survival (mPFS) and toxic effects were pooled and compared within each arm. Thirty-three studies involving 1470 patients were analyzed. In total, 771 and 699 patients were treated by cisplatin/gemcitabine and oxaliplatin/gemcitabine, respectively. Weighted median of mOS was 9.7 months in cisplatin group and 9.5 months in oxaliplatin group. Cisplatin-based chemotherapy was significantly associated with more grade 3 and 4 asthenia, diarrhea, liver toxicity, and hematological toxicity. Sensitivity analysis including only the studies with the standard regimen of cisplatin (25-35 mg/m(2) administered on days 1 and 8) showed that the weighted median of mOS increased from 9.7 to 11.7 months but Gem/CDDP regimen remained more toxic than Gemox regimen. These results suggest that the Gem/CDDP regimen with cisplatin (25-35 mg/m(2)) administered on days 1 and 8 is associated with survival advantage than Gemox regimen but with addition of toxicity.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
xiaoyeken发布了新的文献求助10
1秒前
h11发布了新的文献求助10
1秒前
ilc发布了新的文献求助10
1秒前
Venus发布了新的文献求助10
2秒前
xixi发布了新的文献求助10
2秒前
星辰大海的应助被瘦瘦的老三采纳,获得10
2秒前
热情河马发布了新的文献求助10
3秒前
liuapple完成签到,获得积分10
3秒前
null的应助被超级尔白采纳,获得10
3秒前
4秒前
研友_VZG7GZ的应助被无敌的ybk采纳,获得30
4秒前
zzkkzz完成签到,获得积分10
4秒前
4秒前
4秒前
5秒前
5秒前
简单春天发布了新的文献求助10
5秒前
5秒前
6秒前
6秒前
6秒前
直率的电灯胆的应助被嘟噜采纳,获得10
7秒前
8秒前
ZHANGLI完成签到 ,获得积分10
8秒前
xiaoyeken完成签到,获得积分10
8秒前
搜集达人的应助被Kannan采纳,获得10
8秒前
梦安完成签到 ,获得积分10
8秒前
风吹麦浪的应助被瘦瘦的老三采纳,获得10
9秒前
9秒前
熙可檬发布了新的文献求助10
9秒前
9秒前
颜颜发布了新的文献求助10
10秒前
gao456789发布了新的文献求助10
10秒前
10秒前
Zxs完成签到,获得积分20
11秒前
iaii发布了新的文献求助10
11秒前
11秒前
11秒前
经竺的应助被dde采纳,获得10
11秒前
04d的应助被dde采纳,获得10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8164555
求助须知:如何正确求助?哪些是违规求助? 9558341
关于积分的说明 21745170
捐赠科研通 7755092
什么是DOI,文献DOI怎么找? 3428591
关于科研通互助平台的介绍 2553128
邀请新用户注册赠送积分活动 2473151